Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm, Residual × Dexamethasone × 30 days × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 57 Recurrence 8 Burkitt Lymphoma 8 Precursor Cell Lymphoblastic Leukemia-Lymphoma 7 Immunoglobulin Light-chain Amyloidosis 7 Neoplasms 6 Prostatic Neoplasms 5 Leukemia, Biphenotypic, Acute 4 Paraproteinemias 3 Neoplasm Metastasis 3 Lung Neoplasms 3 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Ovarian Neoplasms 2 Neoplasms, Plasma Cell 2 Lymphoma, Large B-Cell, Diffuse 2 Colorectal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Brain Neoplasms 2 Adenocarcinoma 2 beta-Thalassemia 1 Vomiting 1 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Thalassemia 1 Supratentorial Neoplasms 1 Smoldering Multiple Myeloma 1 Renal Insufficiency 1 Rectal Neoplasms 1 Radiation Pneumonitis 1

Interventions

pembrolizumab 2 fludarabine 2 blinatumomab 2 tislelizumab 1 tisagenlecleucel 1 tetrathiomolybdate 1 relugolix 1 nilotinib 1 isatuximab 1 inavolisib 1 giredestrant 1 fludarabine phosphate 1 enzalutamide 1 abemaciclib 1 Transplantation 1 Neoadjuvant Therapy 1 Monatide (IMS 3015) 1 Melphalan 1 Lenalidomide 1 Immunotherapy 1 Imatinib Mesylate 1 HMPL-013 1 Docetaxel 1 Dexamethasone 1 Dasatinib 1 Cyclophosphamide 1 Chemotherapy, Adjuvant 1 Capecitabine 1 Calcium Dobesilate 1 Biological Assay 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05690984 2026-03-16

EMAT

Medical College of Wisconsin

Phase 2 Active not recruiting

Multiple Myeloma, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡